Spots Global Cancer Trial Database for A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas
Official Title: A Phase II Study of Pemetrexed in Recurrent Cervical Adenocarcinomas
Study ID: NCT02868892
Interventions
Study Description
Brief Summary: Patients with advanced or recurrent adenocarcinoma or adenosquamous cell carcinoma of the cervix will receive Pemetrexed.
Detailed Description: Patients will receive Pemetrexed 500 mg/m2 every three week. On initiation of pemetrexed, on day one of first chemotherapy cycle, patients will begin taking folic acid at a dose of 350 to 600 mcg daily as well as receive an intramuscular injection of 1000 mcg of vitamin B12, with subsequent vitamin B12 injections given every 9 weeks while on study.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Western Regional Medical Center, Inc., Goodyear, Arizona, United States
Contact Details
Name: John Farley, MD
Affiliation: Western Regional Medical Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
